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to the WHO: conclusions and recommendations 
of seventh biannual meeting (March 2015)
WHO Malaria Policy Advisory Committee and Secretariat*
Abstract 
The Malaria Policy Advisory Committee to the World Health Organization held its seventh meeting in Geneva, Switzer-
land from 5 to 7 March 2015. This article provides a summary of the discussions, conclusions and meeting recommen-
dations. Meeting sessions included: an update on the Greater Mekong Subregion elimination strategy; an update on 
the RTS,S vaccine; G6PD testing to support the safe use of anti-relapse therapy for Plasmodium vivax; update from the 
Vector Control Advisory Group; newly proposed evidence reviews or consultations on malaria terminology, malaria 
in pregnancy, and the feasibility of eradication; as well as updates from the World Health Organization Global Malaria 
Programme regarding their strategy update and policy setting processes. Policy statements, position statements, and 
guidelines that arise from the Malaria Policy Advisory Committee meeting conclusions and recommendations will 
be formally issued and disseminated to World Health Organization Member States by the World Health Organization 
Global Malaria Programme.
Keywords: WHO, Malaria, Policy-making, Mosquito control, Drug resistance, Surveillance, Elimination, Plasmodium 
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Background
The Malaria Policy Advisory Committee (MPAC) to the 
WHO held its seventh biannual meeting from 5 to 7 
March 2015 in Geneva, Switzerland, following its meet-
ings in February and September 2012, March and Sep-
tember 2013, and March and September 2014 [1–6]. This 
article provides a summary of the discussions, conclu-
sions and recommendations from that meetinga as part 
of the Malaria Journal thematic series “WHO global 
malaria recommendations” [7].
The following sections of this article provide details 
and references for the meeting sessions on: an update 
on the Greater Mekong Subregion elimination strategy; 
an update on the RTS,S vaccine; G6PD testing to sup-
port the safe use of anti-relapse therapy for Plasmodium 
vivax; update from the Vector Control Advisory Group; 
newly proposed evidence reviews or consultations on 
malaria terminology, malaria in pregnancy, and the fea-
sibility of eradication; as well as updates from the WHO 
Global Malaria Programme (WHO-GMP) regarding 
their strategy update and policy setting process.
The MPAC discussion and recommendations related to 
these topics, which took place partially in closed session, 
are also included. MPAC decisions are reached by con-
sensus [8]. The next meeting of the MPAC will be 16–18 
September 2015 [9].
Report from the WHO Global Malaria Programme
Following a welcome by the chair of MPAC, the Director 
of WHO-GMP gave an overview of the key findings of the 
World Malaria Report 2014 [10]. He provided an update 
about WHO-GMP’s activities over the past 6 months and 
the key programme priorities being pursued in WHO 
regions [11]. Over this period, WHO-GMP issued a 
number of new technical documents, including guidance 
on temporary malaria control measures in Ebola-affected 
countries [12].
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Following the update from the Director of WHO-GMP, 
the Executive Director of the Roll Back Malaria (RBM) 
Partnership gave an update about the process for final-
izing RBM’s Action and Investment to Defeat Malaria 
(2016–2030) [13], which will be a companion document 
to the new WHO Global Technical Strategy for Malaria 
(2016–2030) [14]. Development of the two documents 
has been closely coordinated through seven regional 
consultations, and the documents have the same goals, 
milestones and targets. The RBM Executive Direc-
tor explained that in addition to the regional consulta-
tions, the draft RBM document has been reviewed in 
12 national consultations, and was shaped through over 
120 interviews with key informants. She summarized the 
seven key priorities established in the draft document, 
which should drive future efforts to strengthen political 
commitment, financial resources and the enabling envi-
ronment for malaria efforts [15].
MPAC welcomed plans by WHO-GMP and RBM to 
work with countries on translating the new global guid-
ance documents into action at the national level, and 
highlighted the importance of providing technical sup-
port to ensure that national malaria plans are updated 
and implemented in a timely manner.
Malaria elimination in the Greater Mekong Subregion
The WHO Regional Malaria Advisors from the South 
East Asian and Western Pacific Regional Offices jointly 
presented an update on the Greater Mekong Subre-
gion (GMS) Malaria Elimination Strategy (following 
the recommendation by MPAC at its previous meet-
ing in September 2014 [6] to adopt a Plasmodium fal-
ciparum elimination goal in the GMS by 2030 in order 
to contain multiple foci of artemisinin resistance). The 
strategy has been drafted under the leader-ship of the 
WHO Regional Hub for the Emergency Response to 
Artemisinin Resistance (ERAR), the two Regional Offices 
concerned (SEARO and WPRO) and WHO-GMP. The 
update covered: (a) the strategy development process; (b) 
the proposed goals and targets; and (c) the recommended 
strategic directions to scale up efforts in order to achieve 
malaria elimination of all parasite species by 2030. WHO 
also presented options for a governance structure that 
could drive efforts forward in a more effective way [16].
Overall, MPAC was supportive of the draft strategy and 
agreed with the proposed regional and country priorities. 
The committee noted, however, that the urgency of the 
response should be emphasized more strongly, consid-
eration should be given to accelerating the timelines, and 
there should be a more pronounced mention of the need 
for national political commitment at the highest level. 
MPAC also discussed the importance of multi-sectoral 
engagement, the need to clarify the role of “governance” 
and “management”, and the need to position countries as 
the main drivers of this effort. The committee also raised 
the idea of creating an independent monitoring board to 
assess progress.
After extensive discussion, MPAC members decided to 
share a written response with the strategy drafting com-
mittee, and send a communication to the WHO Direc-
tor-General highlighting the need to treat this issue as an 
urgent public health priority with global implications that 
requires commensurate support and commitment from 
both WHO leadership and development partners.
Update on the latest RTS,S vaccine results and analysis
The Joint Technical Expert Group (JTEG) on the RTS,S 
vaccine presented the latest RTS,S trial results. Consider-
ations about the preparation of a potential WHO policy 
recommendation, and the preliminary data on the cost-
effectiveness and potential impact of RTS,S were also 
presented. These presentations and the discussions that 
followed were closed to the public due to the confidential 
(i.e. unpublished) nature of the results at the time of the 
MPAC meeting. In addition, the discussions were closed 
to MPAC members who had declared a conflict of inter-
est due to involvement in the RTS,S Phase 3 trial.
MPAC will review the available information on RTS,S 
at its next meeting in September 2015. A final decision on 
a potential WHO policy recommendation will be made 
at a joint meeting of MPAC and the Strategic Advisory 
Group of Experts (SAGE)—which is the WHO advisory 
body for vaccines—in October 2015, if a positive scien-
tific opinion from the European Medicines Agency under 
article 58 has been given by then.
Recommendations on testing for glucose‑6‑phosphate 
dehydrogenase (G6PD) deficiency to promote safe use 
of primaquine anti‑relapse therapy
An Evidence Review Group (ERG) convened to review 
new technologies and devices for testing glucose-6-phos-
phate dehydrogenase (G6PD) deficiency at the point of 
care presented MPAC with the results from their 8–9 
October 2014 meeting [17]. In brief, episodes of P. vivax 
malaria, including relapses, which have been long consid-
ered relatively benign, are an important cause of morbid-
ity and mortality in endemic areas. The relapses due to 
untreated P. vivax liver stage infection also make a signif-
icant contribution to transmission. Primaquine, the only 
medicine available for radical cure of P. vivax and Plas-
modium ovale malaria, can induce dose-dependent acute 
haemolytic anaemia (AHA) in G6PD deficient patients. 
The severity of the AHA is variable, but daily primaquine 
anti-relapse therapy can induce potentially life-threat-
ening haemolysis of varying degrees in patients with all 
known G6PD genetic variants that cause deficiency [18].
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Following discussion of the ERG review, MPAC 
concluded that its recommendations relating to the 
treatment of P. vivax malaria were in line with the soon-
to-be-released new edition of the WHO malaria treat-
ment guidelines [19]; therefore the recommendations 
from this MPAC meeting focus on the use of point-of-
care qualitative tests for G6PD deficiency, as follows:
1. G6PD status should be ascertained before the admin-
istration of daily primaquine therapy for 14  days to 
prevent relapses in patients with confirmed P. vivax 
or P. ovale malaria.
2. If patients’ G6PD status is not generally available, 
then G6PD qualitative point-of-care tests should 
be introduced in P. vivax endemic areas to identify 
G6PD non-deficient patients prior to primaquine 
administration. Such tests should be at least 95% 
sensitive for G6PD enzyme activity levels below 30% 
of normal as identified by spectrophotometry or 
equivalent quantitative tests. They should be stable at 
30–40°C.
3. The introduction of point-of-care G6PD tests should 
be accompanied by quality assurance, training, 
supervision, and behaviour change communication 
as well as monitoring of the feasibility, acceptability 
and ease of use of these tests. Lessons from initial 
small-scale deployment should guide decisions on 
expansion of G6PD diagnostic services across the 
health care system.
4. The indications and contraindications for primaquine 
treatment in males and females with G6PD defi-
ciency should follow the recommendations given in 
the WHO Guidelines for the Treatment of Malaria. 
Third edition (in press at the time of the meeting).
Update from the WHO Vector Control Advisory Group
The WHO Vector Control Advisory Group (VCAG) gave 
a presentation about their November 2014 meeting [20], 
and briefed MPAC about a recent VCAG recommenda-
tion concerning a specific long-lasting insecticidal net 
(LLIN) product that contains both a pyrethroid insec-
ticide and a synergist. This product is undergoing addi-
tional field evaluations and evidence review. VCAG 
stressed that there is still an urgent need to develop com-
bination LLINs that incorporate multiple insecticides.
MPAC acknowledged the important progress that is 
being made in product development for malaria vector 
control and called for continued investments and inno-
vation by industry and others in the private sector. The 
committee underlined the urgent need for the devel-
opment and deployment of new insecticides and new 
tools to prevent and manage insecticide resistance and 
residual transmission. It also expressed strong support 
and appreciation for the work done by VCAG. It recom-
mended that WHO-GMP—through the Vector Con-
trol TEG—review available data comprehensively and 
develop recommendations accordingly.
Malaria terminology and proposed ERG on malaria 
in pregnancy
WHO-GMP briefed MPAC about plans to review tech-
nical terminology for malaria [21]. The last comprehen-
sive review, which included over 400 malaria terms, was 
undertaken more than 50 years ago [22]. A desk-review 
process and a drafting committee have been estab-
lished to take this forward, and the draft document will 
be shared with MPAC at its next meeting in September 
2015. Given the breadth of this exercise, the commit-
tee will be reviewing terminology in phases. It will start 
with those that are most relevant to malaria elimination 
and eradication, then move on to terms that have pro-
grammatic relevance and those that may have conflict-
ing definitions. MPAC welcomed this initiative and some 
members suggested that WHO-GMP considers turning 
this into a continuous process for reviewing and updating 
terminology.
WHO-GMP also briefed MPAC on plans for conven-
ing an ERG on malaria in pregnancy [23]. The ERG will 
review emerging evidence on the efficacy, safety, feasi-
bility, acceptability and cost-effectiveness of using inter-
mittent screening and treatment of malaria in pregnancy 
(ISTp) to prevent the consequences of malaria in preg-
nancy [24, 25]. The scope of this ERG will cover: (a) an 
assessment of whether ISTp should be considered a 
potential alternative strategy to intermittent preventive 
treatment of malaria in pregnancy (IPTp) with sulfadox-
ine-pyrimethamine (SP) in areas with low malaria trans-
mission or high SP resistance; (b) a review of the impact 
of SP resistance, transmission intensity and threshold 
maps for potential implementation; and (c) considera-
tion of the safety of using artemisinin derivatives in the 
first trimester of pregnancy on the basis of emerging evi-
dence. The MPAC welcomed the plan and suggested that 
toxicology expertise be included in the evidence review 
process.
Consultation on the feasibility of malaria eradication
WHO-GMP informed MPAC about its plans to convene 
leading malaria experts for a review of the feasibility of 
malaria eradication in the context of increasing interest 
in this topic within the malaria community. The draft 
global technical strategy [14] sets out a vision of a “world 
free of malaria”, and WHO-GMP needs to take an offi-
cial position on how and under what timeline malaria 
eradication could be achieved. WHO-GMP would like 
MPAC to be engaged in a broad technical consultation 
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on the feasibility of eradication, underpinned by a rig-
orous scientific review, which together will lead to the 
development of a robust technical document on how the 
eradication agenda should be taken forward. The docu-
ment would include a comprehensive research agenda 
for eradication, and an analysis of options for moving 
towards that goal.
MPAC agreed to support WHO-GMP in this effort and 
looks forward to receiving a concrete proposal on how 
the process will be set up. The committee suggested that 
WHO-GMP consider using a scenario-based approach 
i.e. of different pathways to malaria eradication based on 
various epidemiological profiles, as this would provide a 
good analytical framework while at the same time help-
ing to make the investment case for malaria in the post-
2015 period. It was suggested that WHO-GMP should 
look at how the various 2030 goals and targets impact on 
each other, and that this assessment includes an analysis 
of social, political, economic, environmental and other 
determinants of epidemiological change.
WHO‑GMP strategy update and policy‑setting
The WHO-GMP Director provided an update on the 
current strategy refresh process within WHO-GMP [26, 
27]. The aim of this process is to re-assess and update the 
department’s strategic priorities in line with the goals and 
targets of the new WHO Global Technical Strategy for 
Malaria (2016–2030) [14]. Following extensive internal 
consultation, the process will lead to the creation of an 
updated team structure that is fully aligned with WHO-
GMP’s new strategic priorities. WHO-GMP acknowl-
edged that the implementation of the new strategy will 
require strengthened human and financial resources 
across the WHO global malaria team. MPAC welcomed 
the initiative and several members highlighted the 
importance of strengthening surveillance systems and 
improving data analysis—on both the disease burden and 
on interventions—in order to maximize the effectiveness 
of malaria responses at the national, regional, and global 
level.
WHO-GMP proposed a streamlining of policy-setting, 
so that MPAC would not be asked to validate all guidance, 
but focus on the key strategic and technical questions on 
which WHO-GMP needs assistance [28, 29]. Concretely, 
the agenda would be determined from a running list of 
priority topics kept and reviewed on a monthly basis by 
WHO-GMP. In general, the reports and recommenda-
tions from TEGs and ERGs should be for information, 
unless they have significant impact, are controversial, 
or are thought by WHO-GMP to require MPAC advice. 
MPAC welcomed the proposal by WHO-GMP and rec-
ommended that the same rules apply regarding the par-
ticipation of MPAC members in TEGs and ERGs. MPAC 
also asked that they continue to receive all TEG and ERG 
reports.
WHO-GMP further informed MPAC that it would 
standardize and improve the materials and dissemination 
of policy recommendations, policy briefs and other guid-
ance to inform national programmes and other stake-
holders. This effort will culminate in the consolidation 
of a “global handbook” to serve as a user-friendly com-
pendium of WHO malaria programme guidance. MPAC 
members welcomed this development.
Discussion
The wording for recommendations were finalized by 
MPAC during their closed session and, in some cases, 
via email following the meeting; conclusions have been 
included in the summaries of the meeting sessions above, 
and links to the full set of meeting documents from the 
open sessions are provided as references.
As has been done following previous meetings, policy 
recommendations in line with MPAC suggestions will 
be issued formally and disseminated to WHO Member 
States by WHO-GMP and the WHO Regional Offices. 
Conclusions and recommendations from MPAC meet-
ings are published in the Malaria Journal as part of this 
series.
On-going engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be 
strong, although it was noted that more can be done 
to publicize open registration, especially to encourage 
attendance by research and development organizations 
who might not otherwise be aware that their presence 
as observers, as with all stakeholders who observe the 
MPAC meetings, is most welcome.
Conclusion
The meeting feedback received from MPAC members, 
participants and observers [30] was generally positive. 
WHO-GMP and MPAC continue to welcome feedback, 
support, and suggestions for improvement of MPAC 
meetings from the global malaria community via the 
WHO-GMP website [9]. The next meeting of the MPAC 
will take place from 16 to 18 September 2015 in Geneva, 
Switzerland. Further information including the agenda 
and registration details will be made available in August 
2015 on the MPAC page of the WHO-GMP website, 
although questions are welcome at any time [9].
Endnotes
aThe complete set of all MPAC March 2015 meeting-
related documents including background papers, pres-
entations, and member declarations of interest can be 
found online at http://www.who.int/malaria/mpac/
mar2015/en/.
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